Guidance, NICE advice and quality standards in development | Guidance

Showing 251 to 260 of 373

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke	Interventional procedures guidance	11 February 2027
Percutaneous thrombectomy for intermediate-risk and high-risk acute pulmonary embolism	HealthTech guidance	7 April 2027
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
Pharmalgen for the treatment of bee and wasp venom allergy	Technology appraisal guidance	TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	24 February 2027
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]	Technology appraisal guidance	17 September 2026